Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVANT: Azithromycin for Low Birthweight Neonates
NCT05763693Phase 4Not yet recruiting
- Sponsor
- University of California, San Francisco
- Start
- Apr 2026
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of azithromycin in Nutritional deficiency and infectious disease (4 arms), sponsored by University of California, San Francisco. Primary endpoint: Weight-for-age Z-score at 6 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
azithromycin
03
Conditions
Nutritional deficiencyinfectious disease
Beyond the preview
Go deeper on NCT05763693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05763693.